Impact of PolygeNic Risk Score for Glaucoma on PsycHosocial OuTcomes (INSiGHT) Study Protocol

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Dec 26

PMID 39724070

Authors

Giorgina Maxwell

Robert Allen

Simone Kelley

Lucinda Hodge

Georgina L Hollitt

Mathias Seviiri

Daniel Thomson

Joshua Schmidt

Jamie E Craig

Sarah Cohen-Woods

Emmanuelle Souzeau

Affiliations

Soon will be listed here.

Abstract

Glaucoma is the leading cause of irreversible blindness with early detection and intervention critical to slowing disease progression. However, half of those affected are undiagnosed. This is largely due to the early stages of disease being asymptomatic; current population-based screening measures being unsupported; and a lack of current efficient prediction models. Research investigating polygenic risk scores (PRS) for glaucoma have shown predictive ability to identify individuals at higher risk. Potential clinical applications include identification of high-risk individuals, resulting in earlier diagnosis and treatment to prevent glaucoma blindness, and adjusted monitoring for low-risk individuals. However, the psychological impact of receiving glaucoma PRS is unknown. There is a critical need to evaluate risk information communication and assess the impact of receiving results, to support clinical implementation of glaucoma PRS testing. In this prospective study, 300 individuals from the GRADE (Genetic Risk Assessment of Degenerative Eye disease) study will be recruited to investigate the psychosocial impact of disclosing polygenic risk results for glaucoma. GRADE aimed to apply PRS testing on 1,000 unexamined individuals aged 50 years or older from the general population and examine a subset of these individuals to assess the clinical validity of PRS to detect glaucoma. In this study, individuals each from the bottom decile (10%), top decile (10%), and middle (45-55%) of the PRS distributions will be invited to receive research glaucoma PRS results. Participants who choose to receive their results will complete up to four questionnaires (prior to receiving their results, and subsequently two-weeks, six- and 12-months after receiving their result). The questionnaires will include health belief model measures and assess glaucoma anxiety, general anxiety and depression, test-related distress, decisional regret, and recall and understanding of results. This research will provide guidance for the implementation of polygenic risk testing into clinical practice and inform delivery strategies.

References

Hsiao Y, Chuang H, Chi S, Wang Y, Chiang P, Teng P . Genome-Wide Polygenic Risk Score for Predicting High Risk Glaucoma Individuals of Han Chinese Ancestry. J Pers Med. 2021; 11(11). PMC: 8618593. DOI: 10.3390/jpm11111169. View

Craig J, Han X, Qassim A, Hassall M, Cooke Bailey J, Kinzy T . Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. Nat Genet. 2020; 52(2):160-166. PMC: 8056672. DOI: 10.1038/s41588-019-0556-y. View

Li M, Bennette C, Amendola L, Hart M, Heagerty P, Comstock B . The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. J Genet Couns. 2019; 28(2):477-490. DOI: 10.1007/s10897-018-0286-9. View

Siggs O, Qassim A, Han X, Marshall H, Mullany S, He W . Association of High Polygenic Risk With Visual Field Worsening Despite Treatment in Early Primary Open-Angle Glaucoma. JAMA Ophthalmol. 2022; . PMC: 9650622. DOI: 10.1001/jamaophthalmol.2022.4688. View

ONeill E, Gurria L, Pandav S, Kong Y, Brennan J, Xie J . Glaucomatous optic neuropathy evaluation project: factors associated with underestimation of glaucoma likelihood. JAMA Ophthalmol. 2014; 132(5):560-6. DOI: 10.1001/jamaophthalmol.2014.96. View

Brehaut J, OConnor A, Wood T, Hack T, Siminoff L, Gordon E . Validation of a decision regret scale. Med Decis Making. 2003; 23(4):281-92. DOI: 10.1177/0272989X03256005. View

Horowitz M, WILNER N, Alvarez W . Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979; 41(3):209-18. DOI: 10.1097/00006842-197905000-00004. View

Singh R, Zhao Y, Elze T, Fingert J, Gordon M, Kass M . Polygenic Risk Scores for Glaucoma Onset in the Ocular Hypertension Treatment Study. JAMA Ophthalmol. 2024; 142(4):356-363. PMC: 10941023. DOI: 10.1001/jamaophthalmol.2024.0151. View

Kasparian N, Meiser B, Butow P, Simpson J, Mann G . Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med. 2009; 11(4):265-78. DOI: 10.1097/GIM.0b013e3181993175. View

10.

Sleath B, Blalock S, Covert D, Stone J, Skinner A, Muir K . The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011; 118(12):2398-402. PMC: 3223548. DOI: 10.1016/j.ophtha.2011.05.013. View

11.

Young M, Yanes T, Cust A, Dunlop K, Limb S, Newson A . Human Genetics Society of Australasia Position Statement: Use of Polygenic Scores in Clinical Practice and Population Health. Twin Res Hum Genet. 2023; 26(1):40-48. DOI: 10.1017/thg.2023.10. View

12.

Tiller J, Bakshi A, Dowling G, Keogh L, McInerney-Leo A, Barlow-Stewart K . Community concerns about genetic discrimination in life insurance persist in Australia: A survey of consumers offered genetic testing. Eur J Hum Genet. 2023; 32(3):286-294. PMC: 10923945. DOI: 10.1038/s41431-023-01373-1. View

13.

Andreoli L, Peeters H, Van Steen K, Dierickx K . Taking the risk. A systematic review of ethical reasons and moral arguments in the clinical use of polygenic risk scores. Am J Med Genet A. 2024; 194(7):e63584. DOI: 10.1002/ajmg.a.63584. View

14.

Garcia-Retamero R, Cokely E . Designing Visual Aids That Promote Risk Literacy: A Systematic Review of Health Research and Evidence-Based Design Heuristics. Hum Factors. 2017; 59(4):582-627. DOI: 10.1177/0018720817690634. View

15.

Wang K, Gaitsch H, Poon H, Cox N, Rzhetsky A . Classification of common human diseases derived from shared genetic and environmental determinants. Nat Genet. 2017; 49(9):1319-1325. PMC: 5577363. DOI: 10.1038/ng.3931. View

16.

Newman-Casey P, Shtein R, Coleman A, Herndon L, Lee P . Why Patients With Glaucoma Lose Vision: The Patient Perspective. J Glaucoma. 2015; 25(7):e668-75. PMC: 4769687. DOI: 10.1097/IJG.0000000000000320. View

17.

Fan B, Cooke Bailey J, Igo Jr R, Kang J, Boumenna T, Brilliant M . Association of a Primary Open-Angle Glaucoma Genetic Risk Score With Earlier Age at Diagnosis. JAMA Ophthalmol. 2019; 137(10):1190-1194. PMC: 6707005. DOI: 10.1001/jamaophthalmol.2019.3109. View

18.

Kolovos A, Hassall M, Siggs O, Souzeau E, Craig J . Polygenic Risk Scores Driving Clinical Change in Glaucoma. Annu Rev Genomics Hum Genet. 2024; 25(1):287-308. DOI: 10.1146/annurev-genom-121222-105817. View

19.

Han X, Gharahkhani P, Hamel A, Ong J, Renteria M, Mehta P . Large-scale multitrait genome-wide association analyses identify hundreds of glaucoma risk loci. Nat Genet. 2023; 55(7):1116-1125. PMC: 10335935. DOI: 10.1038/s41588-023-01428-5. View

20.

Marshall H, Mullany S, Han X, Qassim A, He W, Hassall M . High Polygenic Risk Is Associated with Earlier Initiation and Escalation of Treatment in Early Primary Open-Angle Glaucoma. Ophthalmology. 2023; 130(8):830-836. DOI: 10.1016/j.ophtha.2023.03.028. View